You might have tried every serum, cream, and facial treatment available, only to find the results are temporary or surface-level
Pharmacother ., 78 , 248-256, doi: 10.1016/j.biopha.2016.01.029
Reported side effects Mild local irritation or discomfort at the injection site Headache (typically mild and short-lived) Nausea or dizziness in some patients Sweating Mild fever more commonly reported in post-stroke use, generally manageable with standard antipyretics Contraindications Cerebrolysin is not recommended for individuals with: Active epilepsy or seizure disorders Severe renal (kidney) impairment Known hypersensitivity to any component of the formulation Note: A 2023 Cochrane review noted a potentially higher rate of spontaneous adverse events in some stroke trial subgroups
You will find actionable insights into building effective combination protocols, mitigating side effects, and ensuring you partner with high-quality compounding pharmacies to protect your practice and your patients
Approval is not expected until mid-2026 or 2027 at the earliest
